These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 16541480

  • 1. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA.
    J Rheumatol; 2006 May; 33(5):921-3. PubMed ID: 16541480
    [Abstract] [Full Text] [Related]

  • 2. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT.
    J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
    [Abstract] [Full Text] [Related]

  • 3. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.
    Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, Twisk JW, Dijkmans BA, Lems WF.
    J Rheumatol; 2005 Feb; 32(2):252-5. PubMed ID: 15693084
    [Abstract] [Full Text] [Related]

  • 4. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis.
    Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K.
    Wien Klin Wochenschr; 2002 Dec 30; 114(23-24):1004-7. PubMed ID: 12635469
    [Abstract] [Full Text] [Related]

  • 5. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
    Dahlqvist SR, Engstrand S, Berglin E, Johnson O.
    Scand J Rheumatol; 2006 Dec 30; 35(2):107-11. PubMed ID: 16641043
    [Abstract] [Full Text] [Related]

  • 6. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA.
    Ann Rheum Dis; 2005 May 30; 64(5):765-6. PubMed ID: 15458960
    [Abstract] [Full Text] [Related]

  • 7. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
    Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, van der Meer JW, van Riel PL, Stalenhoef AF, Barrera P.
    Ann Rheum Dis; 2007 Nov 30; 66(11):1503-7. PubMed ID: 17472994
    [Abstract] [Full Text] [Related]

  • 8. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
    Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, Radstake TR, Netea MG, Roest M, Stalenhoef AF.
    Ann Rheum Dis; 2009 Jun 30; 68(6):868-72. PubMed ID: 18635596
    [Abstract] [Full Text] [Related]

  • 9. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
    Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M.
    Ann Rheum Dis; 2008 May 30; 67(5):620-4. PubMed ID: 17720725
    [Abstract] [Full Text] [Related]

  • 10. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis.
    Allanore Y, Kahan A, Sellam J, Ekindjian OG, Borderie D.
    Clin Chim Acta; 2006 Mar 30; 365(1-2):143-8. PubMed ID: 16176811
    [Abstract] [Full Text] [Related]

  • 11. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.
    Semin Arthritis Rheum; 2010 Jun 30; 39(6):442-7. PubMed ID: 19246078
    [Abstract] [Full Text] [Related]

  • 12. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS, Nordvåg BY, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2005 Aug 30; 52(8):2506-12. PubMed ID: 16052584
    [Abstract] [Full Text] [Related]

  • 13. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis.
    Saiki O, Takao R, Naruse Y, Kuhara M, Imai S, Uda H.
    J Rheumatol; 2007 Oct 30; 34(10):1997-2004. PubMed ID: 17787045
    [Abstract] [Full Text] [Related]

  • 14. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2003 Apr 30; 48(4):1015-23. PubMed ID: 12687543
    [Abstract] [Full Text] [Related]

  • 15. Infliximab improves vascular stiffness in patients with rheumatoid arthritis.
    Wong M, Oakley SP, Young L, Jiang BY, Wierzbicki A, Panayi G, Chowienczyk P, Kirkham B.
    Ann Rheum Dis; 2009 Aug 30; 68(8):1277-84. PubMed ID: 18930987
    [Abstract] [Full Text] [Related]

  • 16. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
    Arthritis Rheum; 2006 Dec 30; 54(12):3782-9. PubMed ID: 17133559
    [Abstract] [Full Text] [Related]

  • 17. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis.
    Peters MJ, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF, Dijkmans BA, Twisk JW, de Koning MH, van de Stadt RJ, Nurmohamed MT.
    Ann Rheum Dis; 2007 Jul 30; 66(7):958-61. PubMed ID: 17314120
    [Abstract] [Full Text] [Related]

  • 18. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.
    van Eijk IC, de Vries MK, Levels JH, Peters MJ, Huizer EE, Dijkmans BA, van der Horst-Bruinsma IE, Hazenberg BP, van de Stadt RJ, Wolbink GJ, Nurmohamed MT.
    Arthritis Rheum; 2009 May 30; 60(5):1324-30. PubMed ID: 19404933
    [Abstract] [Full Text] [Related]

  • 19. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy.
    García-Gómez C, Nolla JM, Valverde J, Narváez J, Corbella E, Pintó X.
    Eur J Clin Invest; 2008 Sep 30; 38(9):686-92. PubMed ID: 18837746
    [Abstract] [Full Text] [Related]

  • 20. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr 30; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.